Ablaze Closes $75 Million Series for Targeted Radiopharmaceutical Therapies

Ablaze Pharmaceuticals, a Shanghai-San Diego company, closed a $75 million Series A round for China development of innovative targeted radiopharmaceutical therapies (TRT) against tumor targets. Ablaze was founded by RayzeBio, a San Diego company that also focuses on TRT candidates. Ablaze will bring RayzeBio's products to China along with products from other companies. The A round was co-led by Vivo Capital and AdvanTech Capital with participation from RAYZ Investments and others.  More details.... Share this with colleagues: // //